Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results.
暂无分享，去创建一个
P. Vyas | R. Larson | S. Kambhampati | N. Daver | E. Wang | M. Chao | G. Ramsingh | A. Asch | D. Sallman | G. Mannis | J. Zeidner | Tiffany N Tanaka | W. Chai-Ho | T. Bradley | M. A. Al Malki | D. Jeyakumar | I. Lal | G. Xing | C. Renard